vaccine target News
-
Jeanette presents E-poster at IPVC 2021
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’. Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ...
-
Vitruvian BioMedical Licenses New Alzheimer’s Vaccine Targeting ABeta + TAU
VITRUVIAN BioMedical, Inc. (“VITRUVIAN”), a biotechnology company, today announced obtaining the Exclusive License for a new Therapeutic Vaccine for Alzheimer’s Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. The AD Vaccine, YM7555, is a DNA Vaccine that targets ...
-
BOHS issues interim advisory note on Vaccination in the Workplace
The British Occupational Hygiene Society, a leading scientific charity and the Chartered Society for Worker Health Protection has issued interim advice on vaccination in the workplace. The British Occupational Hygiene Society, a leading scientific charity and the Chartered Society for Worker Health Protection has issued interim advice on vaccination in the workplace. With the ...
-
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ...
-
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first ...
-
Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed. The DKFZ is to make an internal evaluation of Imaxio’s IMX313 pro-immunogenic ...
By IMAXIO S.A.
-
Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is free to attend. ...
-
Imaxio and AJ Biologics announce the execution of a collaboration agreement to extend the commercialisation of Imaxio’s leptospirosis vaccine in Malaysia
Imaxio, a biotech company specialising in immunology, announces today the execution of a license agreement with AJ Biologics, a Malaysian company dedicated to vaccine manufacturing and commercialization, as part of the company’s strategy to extend the distribution of Imaxio’s leptospirosis vaccine in Malaysia. Imaxio is a French SME developing an early clinical stage pipeline of ...
By IMAXIO S.A.
-
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19
Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-19. The research will be carried out in collaboration with the renowned Nuffield Department of Medicine (NDM) at the University of ...
-
BOC Sciences to Exhibit at Drug Discovery Chemistry 2024, Booth #117
BOC Sciences, a tech-driven company, is delighted to announce that its team will be participating in the prestigious Drug Discovery Chemistry (DDC) conference in April 2024. The company will be situated at booth #117, showcasing its quality chemical materials and advanced technologies. DDC is an annual event that gathers researchers, scientists, and experts from across the globe who are involved ...
By BOC Sciences
-
NEC publishes design blueprints for SARS-CoV-2 vaccines using its Artificial Intelligence technology
Oslo, April 22, 2020 – NEC OncoImmunity AS today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development ...
-
Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
-
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment ...
-
NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine
Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially life-saving COVID-19 vaccine. Neovii will work in close collaboration with a team of scientists led by Prof. Jonathan Gershoni of ...
-
Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. Ms. Eagling-Vose brings over 20 years’ ...
-
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other ...
By Vaxxinit
-
Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax-enabled Flu Vaccines
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ...
-
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed ...
-
Ziphius Vaccines and University of Antwerp Announce Collaboration Agreement for Optimized Delivery of saRNA-based Vaccines & Therapeutics
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a dynamic lipid library for optimized delivery systems ...
-
First patient dosed in SCIB1 Phase 2 clinical trial
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab ...
By Scancell
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you